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obesity, hypertriglyceridemia (triglycerides ≥1.7 mmol/L); low high-density lipoprotein (HDL) (cholesterol ≤1.03 mmol/L for men and ≤1.29 mmol/L for women); elevated blood pressure (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg or current use of antihypertensive drugs); impaired fasting glucose (fasting plasma glucose ≥ 5.6 mmol/L). Subclinical Cushing's syndrome (SCS) is the most frequent hormonal abnormality detected in patients with AI with wide variation in prevalence (5-47%) and the issue of subtle cortisol secretion by AIs is among the most controversial issues in endocrine practice. It has been hypothesized that subtle cortisol overproduction in subjects with AI may impact on carbohydrate metabolism. [7] Comparison of groups of patients has generally revealed modest increases in body mass index (BMI), HTN, reduced insulin sensitivity, glucose intolerance or frank diabetes, adverse cardiovascular risk profile, and osteopenia/osteoporosis in patients with SCS compared to controls; however, most of the studies suffer to a degree from referral bias. [8, 9] Nonfunctioning AIs paradoxically have been recently implicated to predispose to metabolic syndrome and increasing evidence supports an association between nonfunctioning AIs and obesity, HTN, hyperglycemia, dyslipidemia, and insulin resistance. [1, 7, [10] [11] [12] [13] This relationship appears to be theoretically inexplicable, as nonfunctioning AIs usually remain inactive; the cause-effect relationship and the underlying mechanisms have not been conclusively delineated and remain to be further elucidated.
Improvement in certain metabolic parameters has also been observed after unilateral adrenalectomy in patients with AIs. The aim of this systematic review is to advance the understanding of the association between nonfunctioning and subclinical autonomous cortisol secreting AIs and components of metabolic syndrome and the long-term clinical implications including surgical outcome, in order to appropriately address the management issues and to formulate suggestions for future research.
Methods

Search strategy
A systematic search was performed for English language articles using MEDLINE, Cochrane Controlled Trials Register , and EMBASE (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) . The literature was searched for the period from each database's earliest inception up to June 2018. In addition, the reference lists of the retrieved articles were examined to identify additional eligible studies. Combinations of keywords were used including "adrenal incidentalomas'' or "adrenal mass," "subclinical Cushing's syndrome'' or "preclinical Cushing's syndrome'' or "autonomous cortisol secretion'', "nonfunctioning adrenal incidentalomas'' in combination with "metabolic syndrome'', or "cardiometabolic'' or "cardiovascular risk'', or "insulin resistance'' in the title or the abstract. The review was conducted in line with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. [14] 
Inclusion and exclusion criteria
Original retrospective, prospective, or cross-sectional studies which analyzed patients with nonfunctioning and/or subclinical cortisol secreting AIs based on their biochemical profile reporting at least two components of metabolic syndrome (diabetes, impaired glucose tolerance, fasting hyperinsulinemia, dyslipidemia, HTN, and obesity/central adiposity) and the results of adrenalectomy and/or conservative management on these outcomes were included.
Studies without biochemically confirmed subclinical hypercortisolism and studies reporting only preoperative data or insufficient postoperative data were excluded from the systematic review, as were case reports and series including fewer than ten operated patients. Data quoted as unpublished or derived from abstracts were not used in the systematic review. The patients in the studies were classified into two groups: nonfunctioning AIs and subclinical cortisol secreting AIs. Nonfunctioning AI was defined as a subgroup of AI where the possibility of profound or even subclinical adrenal hormone excess was ruled out based on a comprehensive endocrine evaluation. Subclinical cortisol secreting AI was defined as a subgroup of AI with an abnormal response to standard tests of hypothalamic-pituitary-adrenal (HPA) axis function.
A predesigned data extraction form was used to collect data from the eligible studies. All variables were listed for which data were sought and information was extracted from each study including: 1) first author's last name, country, study design, number of participants; 2) age range and gender of study participants; 3) endocrine tests performed for autonomous cortisol secretion; 4) AI category: subclinical autonomous cortisol secreting or non-functioning; 5) outcome measures including, a) prevalence of components of metabolic syndrome in subclinical cortisol secreting AIs and nonfunctioning AIs, b) cardiometabolic outcomes of conservative management and adrenalectomy.
Methodological quality and risk of bias assessment
NIH quality assessment tool for observational cohort and cross-sectional studies was used to assess the risk of bias. It is based on the key concepts for evaluating the internal validity of a study; the critical assessments are made separately and are divided into 14 set of questions. [15] 
Results
The literature search yielded 65 publications in total. After screening abstracts for relevance, 36 full-text articles were assessed for eligibility and after applying the inclusion/ exclusion criteria, 18 studies were included in the systematic review. Quantitative meta-analysis was not performed owing to significant clinical heterogeneity among the studies. A flow chart of this process is presented in Figure 1 . studies were included in the systematic review. Studies were mostly from European centers; 9 of the studies originated from Italy, [2, [16] [17] [18] [19] [20] [21] [22] [23] 4 from Japan, [24] [25] [26] [27] 2 from Greece, [28, 29] and 1 each from Turkey, [30] Hungary, [31] and Korea. [32] The studies were published between 2002 and 2017. They involved in total 1772 patients with AI. Of these, 1028 (58%) had nonfunctioning AI, while 500 (28.2%) had SCS. The main characteristics and demographics of the studies and outcome definitions are presented in Tables 1 and 2, respectively. Diagnostic criteria or definition of SCS were heterogeneous in the studies, as presented in Table 3 . They were mostly based on high morning cortisol concentrations after dexamethasone suppression test (DST) combined with at least one other test of HPA axis function.
All the studies included in the systematic review had patients with subclinical cortisol secreting AIs and half of the studies had patients with nonfunctioning AIs. The clinical characteristics at baseline and outcome on follow-up in patients with SCS are presented in Table 4 .
Out of 18 studies included in the review, 9 had patients with nonfunctioning AIs, 3 of the studies had no follow-up data, so they were only used for comparison between SCS and nonfunctioning AIs at baseline. [2, 17, 32] The clinical characteristics at baseline and outcome on follow-up in patients with nonfunctioning AIs are presented in Table 5 .
Six studies compared the prevalence of cardiometabolic risk factors in patients with nonfunctioning AIs and subclinical cortisol secreting AIs. [2, [16] [17] [18] 29, 32] The comparison is presented in Table 6 .
The systematic review demonstrated higher prevalence of HTN, impaired glucose metabolism, dyslipidemia, and raised BMI in patients with subclinical cortisol secreting AIs as compared to patients with nonfunctioning AI. In patients with SCS surgical intervention had a beneficial effect on blood pressure, glucometabolic control, and obesity when compared with conservative management. The results for lipid metabolism were equivocal. There was no significant improvement in cardiometabolic risk factors after adrenalectomy in patients with nonfunctioning AIs. Summary of the results is presented in Table 7 .
Quality assessment and risk of bias
Most of the studies included in the systematic review were observational cohort studies, two were cross-sectional studies, and there was a single Randomized controlled trial (RCT). The methodological quality of the studies was therefore assessed using the NIH quality assessment tool for observational cohort and cross-sectional studies. [15] Figure 1: PRISMA flowchart of study selection process 
Contd...
In view of inclusion of only a single RCT which was available on the review subject, it was suspected that the quality of evidence would be very low or poor. However, the assessment using the tool specifically designed for observational cohort and cross-sectional studies revealed that the quality of evidence was low to moderate or "fair" as per the NIH tool.
The risk of bias was mainly due to lack of confirmed presence of exposure prior to the outcomes; lack of sample size justification; heterogeneity between studies for diagnostic protocols, definitions of outcome and duration of follow-up; lack of blinded outcome assessments; and absence of adjustment for confounders. The results of quality assessment [29] NA NA NA NA Di Dalmazi et al. [17] Obesity not in outcome SBP ≥140 and/or DBP ≥90 measured on at least 2 separate occasions and/or antihypertensive treatment T2DM: OGTT as per the ADA position statement [33] and/or treatment with antidiabetic drugs
Total cholesterol ≥200 mg/dl and/or Triglycerides ≥150 mg/dl Erbil et al. [30] Obesity [20] NA SBP ≥140 and/ or DBP ≥90 and/ or antihypertensive treatment WHO criteria [34] Triglycerides ≥150 mg/dl or HDL <40 mg/dl in men HDL <50 mg/dl in women or on anti-dyslipidemic treatment Iacobone et al. [19] Overweight [25] NA NA NA NA Perysinakis et al. [28] Obesity [21] NA NA NA NA Metabolic syndrome defined by ATP III-NCEP criteria [35] Contd... of individual studies as per NIH quality assessment tool are presented in Table 8 .
dIscussIon
Systematic review of studies with heterogeneous and limited published data suggest increased prevalence of components of metabolic syndrome in subclinical cortisol secreting and nonfunctioning AIs; a beneficial role of adrenalectomy on HTN, glucometabolic control, and BMI was observed in patients with subclinical cortisol secreting AIs.
For SCS, baseline prevalence of abnormal glucose metabolism ranged from 16.6% to 90%, HTN from 33 to 85%, high BMI from 25 to 80%, and dyslipidemia from 9 to 90% in the included studies. There were lesser number of studies on nonfunctioning AIs in the present review and the baseline prevalence of abnormal glucose metabolism ranged from 9% to 27%, HTN from 24% to 86%, high BMI from 27% to 63%, and dyslipidaemia from 5% to 60%. One study also looked into the prevalence of cardiovascular events and showed increased prevalence in patients with SCS [20] and another study reported increased prevalence of coronary heart disease and stroke in SCS. [17] Studies assessing surgical outcome in SCS patients showed significant improvement in blood pressure from baseline in most of the studies, improvement in glucose metabolism in more than half, and improved BMI in more than a third of the studies. In the study by Petramala et al., [21] where outcome on metabolic syndrome (as per ATP III criteria) [35] was studied, there was significant improvement in metabolic syndrome following adrenalectomy in SCS patients. For the conservatively managed SCS group, only a single study showed a significant worsening of HTN.
There was no significant improvement in any of the cardiometabolic parameters in patients with nonfunctioning AIs who underwent adrenalectomy. One study [31] showed significant worsening in diabetes and dyslipidemia. For the conservatively managed patients with nonfunctioning AIs, follow-up data showed significant worsening of diabetes in a quarter of the included studies and worsening of dyslipidemia in half of them. There was no significant worsening of the other metabolic parameters in any of the studies.
The summary of results is presented in Table 7 .
When the prevalence of cardiometabolic risk factors was compared between patients with nonfunctioning and subclinical cortisol secreting AIs, parameters of glucose metabolism and dyslipidemia were significantly worse for patients with SCS in most of the studies. However, there was no significant difference between the two groups for HTN and BMI. When the operated groups of nonfunctioning AI and SCS were compared in the study by Chiodini et al., there was significant improvement in diabetes, HTN, and obesity in surgically treated SCS patients. [16] Comparison of prevalence of cardiometabolic risk factors between SCS and nonfunctioning AI is presented in Table 6 .
The reason for a higher prevalence of cardiometabolic risk factors in patients with subclinical cortisol secreting AIs may be subtle or intermittent autonomous cortisol hypersecretion and the outcomes might have been related not only to the degree but also on the duration of hypersecretion, as well as the sensitivity of each individual to cortisol excess. As most patients with AIs are of an age when HTN, diabetes, and obesity are highly prevalent, establishing whether these metabolic complications are truly related to excess cortisol in a patient with an AI is not clear-cut.
Results from studies on outcomes of adrenalectomy have been conflicting but in general, the data indicated an improvement in metabolic complications, especially in blood pressure and diabetes, in patients with subclinical cortisol secreting AI after unilateral adrenalectomy, and deterioration or no improvement in patients treated conservatively. Five studies in the review directly compared the difference between surgical and medical outcomes and assessed changes in cardiovascular risk factors in the long term [19, 21, 23, 24, 27] including one prospective randomized study. [23] Petramala et al. also investigated metabolic syndrome (as per ATP III criteria) [35] and the ambulatory BP (nondipper profile) and found a significant improvement in metabolic syndrome and nondipper profile in SCS group managed by adrenalectomy. [21] There is no consensus on management of SCS associated with AIs and one major issue is that there is no formal agreement as to its definition. The overnight low-dose DST is favored as the most sensitive screening test in patients with AI based [29] Absence of clinical signs of cortisol excess, and Post LDDST cortisol ≥50 nmol/l plus at least one other abnormal test of HPA axis: low ACTH, abnormal cortisol rhythm (plasma cortisol at 24·00 : 8·00% ratio >50%), high UFC, low for age DHEAS Di Dalmazi et al. [17] Absence of clinical signs or symptoms specific to overt CS, and For SCS-post 1 mg overnight DST cortisol >138 nmol/l with no other additional tests For intermediate phenotypes-overnight DST cortisol 50-138 nmol/l plus one other abnormal test (low ACTH and high 24 h UFC) Erbil et al. [30] No symptoms directly attributed to the disease, and Both LDDST and HDDST failed to suppress cortisol <3 µg/dl Toniato et al. [23] No clinical signs of hormone excess, and 1 mg overnight DST >2.5 µg/dl and 1 other HPA axis functional alteration Morelli et al. [20] Absence of signs of overt hypercortisolism, and Post 1 mg overnight DST cortisol levels >5 µg/dL (138 nmol/L) or 2 of the 3 abnormalities of HPA axis: suppressed ACTH, increased UFC, and 1 mg-DST cortisol levels >3.0 µg/dL (83 nmol/L) Iacobone et al. [19] Absence of clinical features of CS, and Post 1 mg overnight DST cortisol >5 µg/dL, morning ACTH suppressed and increased 24 h UFC Maehana et al. [25] Absence of clinical features of CS, and Normal basal cortisol, post 1 mg ODST cortisol >3 µg/dl plus one of: suppressed ACTH, loss of cortisol circadian rhythm, low DHEAS, or unilateral visualisation on adrenocortical scintigraphy Perysinakis et al. [28] Absence of clinical signs of cortisol excess, and Post LDDST Cortisol ≥1.8 µg/dl plus at least one other abnormal test of HPA axis: suppressed ACTH, raised 24 hours UFC, midnight cortisol/morning cortisol percent ratio >50%. Raffaelli et al. [22] Absence of clinical features of overt CS, and Post 1 mg overnight DST cortisol >18 ng/mL plus at least 2 criteria of the following: suppressed basal ACTH levels, high UFC, altered circadian cortisol rhythm & unilateral uptake on adrenocortical scintigraphy Kawate et al. [24] Absence of typical CS features, and Post 1 mg overnight DST cortisol >1.8 µg/dl, low morning ACTH, increased uptake on adrenal scintigraphy, no diurnal changes in cortisol level and low DHEAS. Miyazato et al. [26] Diagnosed as SCS by the endocrinology team, criteria not mentioned Petramala et al. [21] Absent overt clinical signs of hypercortisolism, and 2 or more HPA axis function test abnormality: High UFC, morning cortisol >1.8 µg/dl after 1 mg overnight DST, morning ACTH levels suppressed Tsuiki et al. [27] Lack of characteristic features of CS, and Normal basal cortisol, cortisol >3 µg/dl after 1 mg overnight DST and cortisol >1 µg/dl after 8 mg overnight DST plus at least one of the additional criteria: suppressed basal ACTH levels, altered circadian cortisol rhythm, decreased DHEAS & unilateral uptake on adrenocortical scintigraphy Terzolo et al. [2] Absence of classical clinical features of CS, and Two of the following criteria: Elevated UFC, failure of cortisol to suppress to <138 nmol/l after 1 mg overnight DST, suppressed ACTH concentrations, and disturbed cortisol circadian rhythm Kim et al. [32] Lack of specific symptoms or signs of CS, and Elevated 24 hUFC and low morning ACTH (LDDST to increase diagnostic specificity of CS, but not a criteria for SCS in the study) CS: Cushing's syndrome, ACTH: Adrenocorticotropic hormone, SCS: Subclinical Cushing's syndrome, UFC: Urinary free cortisol, DST: Dexamethasone suppression test, DHEAS: Dehydroepiandrosterone sulfate, LDDST: Low dose dexamethasone suppression test on pathophysiological reasoning, simplicity, and the fact that the test was incorporated in the diagnostic algorithms of most studies. [36] As patients lack the classical clinical features of Cushing's syndrome, it is difficult to determine the true value of the test. Diagnosing SCS by arbitrary cut-offs of cortisol secretion leads to unavoidable misclassifications in some patients. Therefore, additional tests in combination with the dexamethasone test are usually required to validate the biochemical diagnosis of hypercortisolism, although each has some limitations.
Increased prevalence of cardiometabolic risk factors was also observed in nonfunctioning AIs, although less than subclinical cortisol secreting AIs. It is speculated that the nonfunctioning AIs may not be entirely nonsecretory and may constitute an almost continuous spectrum of heterogeneous endocrine abnormalities. They may not produce adrenocortical hormones in sufficient amounts to cause clinically apparent disease or be detected biochemically, but they may have subtle qualitative alterations of steroidogenesis, which might adversely affect various metabolic pathways. [37, 38] The studies included in the current review did not reveal any significant impact of surgery on cardiometabolic morbidities in nonfunctioning AIs and there was significant worsening in diabetes and dyslipidemia in one study. [31] Some studies on nonfunctioning AIs suggest improvement in parameters of metabolic syndrome after surgical treatment; [11, 12, 39] however, they were not included in the review due to small number of operated patients. One of the likely explanations for this observation could be a potential misclassification of patients; for example, one study described that a significant proportion of patients with nonfunctioning AIs developed adrenal insufficiency after surgery, clearly suggesting that autonomous glucocorticoid production was not recognized preoperatively. [39] Overall, glucocorticoid production has been linked to HTN, abnormal glucose tolerance, and increased BMI. [40] Therefore, it is also possible that a temporary reduction of the glucocorticoid load caused by unilateral adrenalectomy could have contributed to a short-term improvement in blood pressure described in patients with nonfunctioning AIs. 
Strengths and limitations
This systematic review has important strengths including an in-depth and comprehensive literature search, focused review questions, predefined inclusion and exclusion criteria, and use of standard quality assessment tool.
Limitations were heterogeneity in definitions of SCS in the studies with variable definitions of endpoints and outcomes and wide variations in length of follow-up. The length of time these metabolic risk factors were present was unknown. Groups also varied in the medical treatment for cardiovascular risk factors and it was unclear in the studies how aggressive the conservative management was in nonoperated patients.
Subgroup analysis of age, gender, and size of the AI which might influence cardiovascular outcomes, was not possible, as individual variables were not consistently reported.
Future research directions
There is a clear need for prospective and appropriately powered studies to evaluate disease-specific and all-cause mortality and other hard clinical endpoints (i.e., myocardial infarction or stroke) to assess the potential cardiovascular morbidity associated with subclinical cortisol secreting AIs and nonfunctioning AIs and to substantiate whether surgical excision is beneficial in these patients. Such studies on subclinical cortisol secreting AI should also provide evidence for a suitable biochemical definition of autonomous cortisol secretion and help define the optimal investigation algorithm that balances the false-positive and negative endocrine test rates. Establishment of an international collaborative study group to develop a database of patients with clinically silent adrenal adenomas might be a useful step in this regard.
conclusIons
Available low-to-moderate-quality evidence obtained from heterogeneous studies in this systematic review with at least 12 months of follow-up suggests increased prevalence of components of metabolic syndrome in patients with subclinical cortisol secreting and nonfunctioning AIs. Screening for independent cardiometabolic risk factors in patients with subclinical cortisol secreting AI is recommended and careful evaluation and long-term follow-up are required. Adrenalectomy might be considered for patients with mild hypercortisolism when medical treatment fails and there is progression of cardiovascular risks. Patients with subclinical cortisol secreting AI who are not candidates for surgery should be followed up clinically to detect, treat, and control cardiovascular risk factors. Until more data are available, a flexible approach guided by clinical judgment is recommended. Giordano et al. [18] NFAI 102 SCS 16
Vassilatou et al. [29] NFAI 57 SCS 20
P=0.98 (NS)
P=0.10 (NS)
P=0.9 (NS) NA Di Dalmazi et al. [17] NFAI 
